Using IHC assays through TMAs, this study identified a two-gene signature that discriminated these two subtypes when combined with the universal fibroblast marker PI16, which were able to predict the clinical hormone response of EMs patients. This evidence concerns the gene PI16 and eosinophilia-myalgia syndrome.